Sectors
TERN
Terns Pharmaceuticals, Inc.
52.93
2 x 38.12
2 x 67.77
bid
ask
+
0.01
0.02%
2 @ 04:00 PM
52.96 +0.03 (0.06%)
| Ytd | 31.01% | |
| 1y | 1503.94% |
52.92
day range
52.95
2.65
52 week range
53.19
| Open | 52.95 | Prev Close | 52.92 | Low | 52.92 | High | 52.95 | Mkt Cap | 6.11B |
| Vol | 1.75M | Avg Vol | 5.71M | EPS | -1.03 | P/E | N/A | Forward P/E | -35.97 |
| Beta | -0.38 | Short Ratio | 0.70 | Inst. Own | 110.02% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 48.67 | 200-d Avg | 27.28 | 1yr Est | 53.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-14 | 2026-03 | 0 | N/A | N/A | N/A |
| 2026-04-02 | 2025-12 | 0 | N/A | N/A | N/A |
| 2025-11-10 | 2025-09 | 0 | N/A | 0.03 | 10.00% |
| 2025-11-10 | 2025-09 | 0 | N/A | N/A | N/A |
| 2025-08-05 | 2025-06 | 0 | N/A | 0.02 | 7.14% |
| 2025-08-05 | 2025-06 | 0 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-04-27 | Oppenheimer | Downgrade | Outperform | Perform |
| 2026-04-14 | JP Morgan | Upgrade | Overweight | Overweight |
| 2026-03-31 | Truist Securities | Downgrade | Buy | Hold |
| 2026-03-30 | Barclays | Downgrade | Overweight | Equal-Weight |
| 2026-03-26 | Citizens | Downgrade | Market Outperform | Market Perform |
| 2026-03-26 | TD Cowen | Downgrade | Buy | Hold |
Profile
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-03-15 | BURROUGHS AMY LOUISE | Chief Executive Officer | 297.30K | Sale |
| 2026-01-13 | GENGOS ANDREW | Chief Financial Officer | 101.79K | Stock Award(Grant) |
| 2024-07-15 | GORDON CARL L | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
| 2026-03-31 | KURIAKOSE EMIL T. | Officer | 105.67K | Sale |
| 2024-09-11 | LU HONGBO B | Director | 0.00 | Purchase |
| 2024-07-15 | ORBIMED ADVISORS, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | Blackrock Inc. | 8.19M | 433.72M | 7.09% |
| 2025-12-30 | Morgan Stanley | 7.95M | 420.56M | 6.88% |
| 2025-12-30 | Adage Capital Partners GP L.L.C. | 5.55M | 293.76M | 4.80% |
| 2025-12-30 | Vanguard Group Inc | 5.52M | 292.38M | 4.78% |
| 2025-12-30 | Vivo Capital, LLC | 5.35M | 283.01M | 4.63% |
| 2025-12-30 | Vestal Point Capital, LP | 4.50M | 238.19M | 3.90% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.18M | 168.58M | 2.76% |
| 2026-02-27 | iShares Trust-iShares Russell 2000 ETF | 2.09M | 110.49M | 1.81% |
| 2026-01-30 | LORD ABBETT SECURITIES TRUST-Lord Abbett Growth Leaders Fund | 1.59M | 84.09M | 1.38% |
| 2026-02-27 | Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.08M | 57.12M | 0.93% |
| 2025-12-30 | SmallCap World Fund Inc | 1.06M | 56.11M | 0.92% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 927.85K | 49.11M | 0.80% |
Split
| Split | Date |
|---|---|
| 2 : 1 | 2000-05-05 |
